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Cephalothin (cefalotin) pharmacokinetics were evaluated for nine severely burned patients (42% 9% mean
burn areas) and five healthy volunteers by using non-plasma-protein-bound concentration-time profiles. Burn
patients gave increased mean residence times (36%) and reduced total clearances (25%). Mean residence times
and distribution volumes increased between 1 and 4 days posttrauma, suggesting that burn patient pharma-
cokinetics change during the initial fluid resuscitation phase of treatment.
Interpatient variability is a consistent feature of burn patient
pharmacokinetics (2). Fluid shifts between different body com-
partments, fluid resuscitation, and effects of surgery all have
impacts on the pharmacokinetics of critically ill patients in a
variable and unpredictable manner (10, 11). We recently reported
that interstitial concentrations of cephalothin (cefalotin) were
maintained significantly longer in burnt and nonburnt subcutane-
ous tissues of burn patients than in those of healthy individuals
(4). In the current study, we examine the unbound plasma ceph-
alothin pharmacokinetics of the same burnt and nonburnt indi-
viduals. The aim was to provide evidence in support of our pub-
lished hypothesis that increased cephalothin exposure of burnt
and nonburnt tissue sites is a consequence of severe burn injury
and the management of shock by fluid resuscitation.
This study was an open-label, single-center pharmacokinetic
study of cephalothin in patients with 28% body surface area
(BSA) burns during burn debridement surgery within 4 days of
trauma. Nine burn patients and five healthy volunteers were
studied. The predicted theoretical benefit of prophylactic
-lactam use in this patient cohort has already been discussed
(5), and interstitial concentrations of cephalothin have been
reported previously for each volunteer and for six of the burn
patients (4). The protocol received approval from the Hospital
and University of Queensland Human Research Ethics Com-
mittees. Written informed consent was obtained from the legal
guardians of the enrolled patients and from the healthy volun-
teers. Detailed descriptions of the research protocols have
been published previously (4, 5). Briefly, patients received 1 g
cephalothin in 10 ml 0.9% saline for 5 min through a dedicated
lumen of a central venous catheter within 1 h of surgery com-
mencement; volunteers received the same treatment via a fore-
arm vein. Blood sampling into heparinized Vacutainers (BD,
NJ) commenced upon the start of the infusion at stipulated
time intervals (5, 10, 20, 30, 60, 120, and 240 min); plasma
samples were stored at 20°C and analyzed within 1 week of
collection. Methods for plasma analysis by isocratic high-per-
formance liquid chromatography with UV detection and rele-
vant assay validation details, have been published elsewhere
(5). Unbound cephalothin data were calculated from total
plasma cephalothin by correcting for percent plasma binding
observed in prestudy plasma samples for each individual.
Briefly, 500 l of 100 g/ml cephalothin in plasma was incu-
bated (37°C for 30 min) and ultracentrifuged (12,000 g for 20
min) through 30-kDa-nominal-cutoff membrane devices (Ami-
con YM30; Millopore Corporation, Billerica, MA) to give a
filtrate yield of approximately 25% original volume, which was
analyzed by high-performance liquid chromatography.
Unbound cephalothin plasma concentration-time data
were analyzed using biexponential regression (C  A et 
B et), applying 1/y2 weighting to account for assay heterosce-
dasticity (1). Terminal elimination half-life (t1/2) was defined
as 0.693/, where  is the terminal elimination rate constant,
taken from C. The maximal plasma cephalothin concentrations
(Cmax) were the observed values. Area under the curve (AUC)
and area under the first moment curve (AUMC) for unbound
cephalothin plasma profiles were calculated by the linear trap-
ezoidal method and extrapolated to infinity, where AUC0–	 is
defined as AUC0–t  Ct/ and where AUMC0–	 is defined as
AUMC0–t  (t  Ct/)  Ct/
2. Total clearance (CLT) was de-
fined as dose/AUC0–	 and was normalized for body weight.
Mean residence time (MRT) was defined as AUMC0–	/
AUC0–	 minus mean infusion time, which was defined as in-
fusion time/2. Effective half-life (t1/2) was defined as
0.693  MRT. Apparent volume of distribution under steady-
state conditions (Vss) was defined as CLT  MRT and was nor-
malized for body weight. Statistical analysis was performed
with SPSS version 16.0.1 for Windows (SPSS, Inc.), and the R
computing language was used to compile plots (R Develop-
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ment Core Team [http://www.r-project.org/]). Nonpaired t tests
with correction for unequal variance (verified by Levene’s f
test) were applied, except for t1/2 data, which, being homosce-
dastic, were analyzed without correction.
Demographics for the nine patients are given in Table 1,
consisting of data compiled from intensive care unit records,
including plasma protein analysis, sepsis-related organ failure
assessment (12), and acute physiology and chronic health eval-
uation (8) data. Total burn surface area (TBSA), subcatego-
rized as partial thickness (second-degree) and full thickness
(third-degree) burns, was assessed by the same burn surgeon
throughout. Total body surface area (BSA) was calculated by
the method of Gehan and George (7). Patient and volunteer
creatinine clearance (CLCR) levels were estimated by Pathol-
ogy Queensland (Herston, Queensland) from prestudy plasma
samples and an 8-hour urine sample collection (3). The demo-
graphics for the five healthy volunteers (mean 
 standard
deviation [SD]) were as follows: age, 35 
 10 years; height,
1.73 
 0.12 meters; weight, 68 
 13 kg; BSA, 1.82 
 0.23 m2.
The pharmacokinetics data are presented in Table 2. Pa-
tients with burn injury had a 45% increase in observed Cmax
(P  0.05; t test), a 25% reduction of cephalothin CLT (P 
0.05; t test), and a 36% increase in MRT (P  0.05; t test) in
comparison to healthy volunteers. Effective plasma t1/2 was
also increased in patients with burns in comparison to levels for
healthy volunteers (P  0.05; t test), reflecting the increased
MRT since t1/2 is 0.693  MRT. Terminal elimination t1/2 had
a trend of being longer in patients than in healthy volunteers
that was not statistically significant (P  0.08; t test). The
differences between patients and healthy volunteers in AUC0-	
and Vss were not statistically significant. Lower percentages of
plasma protein binding of cephalothin were observed for pa-
tients with burns than for healthy individuals (59% 
 8%
versus 71% 
 2%; P  0.001), and higher mean CLCR values
were recorded for patients with burns than for healthy in-
dividuals (148 
 75 ml/min versus 98 
 19 ml/min; P 
0.001; t test).
The dependent pharmacokinetic variables of MRT are Vss
and CLT (since MRT is Vss/CLT), and accordingly, there were
significant associations between MRT and both Vss and 1/CLT
(r  0.727 [P  0.05] and r  0.798 [P  0.01], respectively).
Aberrant pharmacokinetics in burn patients have previously
been shown to exhibit covariance with amount of time follow-
ing burn trauma (9), and in this study, MRT correlated posi-
tively with number of days posttrauma (r  0.727; P  0.05)
(Fig. 1). Interestingly, Vss also correlated with number of days
TABLE 1. Patient demographics and health assessment scores
Patient Sex Age
a
(yr) Ht
a (m) Wt
a,e
(kg) BSA
a (m2) TBSA(% 3rd/% 2nd)c
Scorea,b
No. of days
posttrauma
Concn (g/liter)d
APACHE
II SOFA
Plasma
protein Albumin Globulin
1 Male 54 1.75 88 2.09 15/15 15 7 2 46 30 16
2 Male 25 1.80 70 1.88 26/27 14 5 2 44 27 17
3 Male 23 1.79 80 2.00 25/10 15 3 3 34 18 16
4 Male 42 1.80 80 2.01 38/10 15 5 4 44 22 22
5 Male 23 1.84 90 2.15 25/20 15 5 1 46 30 16
6 Male 50 1.73 90 2.10 12/16 13 9 3 47 29 18
7 Male 49 1.70 70 1.83 0/45 9 6 1 44 28 16
8 Male 23 1.78 100 2.24 51/3 21 7 1 30 18 17
9 Female 31 1.60 55 1.58 30/10 8 6 2 37 26 11
Mean (SD) 36 (12) 1.75 (0.07) 80 (13) 1.99 (0.19) 25/17 (14/12) 14 (4) 6 (2) 2 (1) 41 (6) 25 (5) 17 (2)
a Observations made upon admission to the intensive care unit.
b SOFA, sepsis related organ failure assessment; APACHE II, acute physiology and chronic health evaluation.
c TBSA assessment is itemized by wound depth (3rd, full thickness; 2nd, partial thickness) based on data from burn surgery records.
d Observations made upon the day of study.
e Estimated values.
TABLE 2. Pharmacokinetics of unbound cephalothin in patients with severe burns and in a healthy volunteer control group
Patient Cmax(mg/liter)
AUC0–	
(mg/h/liter) MRT (h) t1/2 (h)
Vss
(liters/kg)
CLT
(liters/h/kg) t1/2 (h)
CLCR
(ml/min)
% Protein
binding
1 30.5 13.36 0.95 0.66 0.81 0.85 1.25 163 65
2 32.9 7.00 0.39 0.27 0.79 2.04 0.81 202 63
3 24.6 12.76 0.73 0.51 0.72 0.98 0.86 169 46
4 35.9 15.72 1.07 0.74 0.85 0.80 1.17 81 62
5 32.1 6.92 0.30 0.21 0.48 1.61 0.76 170 72
6 21.8 10.05 0.58 0.40 0.64 1.11 0.91 64 65
7 65.9 14.63 0.45 0.31 0.44 0.98 0.95 125 58
8 23.6 7.00 0.35 0.24 0.50 1.43 0.66 307 51
9 80.9 21.01 0.53 0.37 0.46 0.87 0.82 52 52
Mean (SD) for:
Patients 38.7 (19.4) 12.05 (4.52) 0.59 (0.25) 0.41 (0.18) 0.63 (0.16) 1.19 (0.40) 0.91 (0.18) 148 (75) 59 (8)
Volunteers (n  5) 21.3 (5.5) 9.89 (2.83) 0.38 (0.03) 0.26 (0.02) 0.60 (0.09) 1.58 (0.15) 0.74 (0.12) 98 (19) 71 (2)
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posttrauma (r 0.724; P 0.05), but 1/CLT did not (r 0.515;
nonsignificant), indicating that alterations in tissue distribution
as opposed to changes in renal function underlie altered MRT
in this burn patient cohort.
We previously reported increased exposure of both burnt and
nonburnt subcutaneous tissues to cephalothin in burn patients
compared with healthy volunteers (4). This increased peripheral-
tissue residence time appears to be reflected in the MRT calcu-
lated from unbound plasma data. The cumulative effects on tissue
fluid volume of systemic inflammatory response syndrome, net
fluid loading, and impaired lymphatic drainage build up during
the resuscitative phase of burn treatment. We have shown that
MRT and its dependent variable Vss also increase during this
period. We conclude that tissue pharmacokinetics play a decisive
role in determining unbound plasma pharmacokinetics in burn
patients and speculate that aberrant antimicrobial pharmacoki-
netics may be an unanticipated consequence of excessive fluid
resuscitation (6) or an effect of the inflammatory response itself
(11).
This work was funded by the National Health and Medical Research
Council of Australia (grant no. 351519).
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FIG. 1. Relationship between number of days following burn
trauma and cephalothin (cefalotin) MRT for patients with severe
burns. Linear fit: y  0.1975  x  0.1775.
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